| Literature DB >> 28641455 |
Irida Th Dhima1, Dimitrios Peschos1, Yannis V Simos1, Maria I Gkiouli2, Maria E Palatianou1,3, Vasilios N Ragos4, Vasiliki Kalfakakou1, Angelos M Evangelou1, Spyridon Ch Karkabounas1.
Abstract
The aim of this study was to investigate the cytotoxic effect cisplatin in combination with epigallocatechin-3-gallate (EGCG) on leiomyosarcoma cells (LMS cells) in order to identify a less toxic but equally effective alternative. Assays for cell proliferation, colony formation efficiency, induction of apoptosis and cell cycle arrest were performed using the IC50 of cisplatin (8.6 μΜ) as a reference value and a concentration of EGCG (30 μΜ) that caused a non-significant reduction in cell proliferation. Pre-treatment of cells with EGCG for 24 h before the addition of cisplatin increased cytotoxicity up to 8.5% (p < 0.05) and the number of apoptotic cells by 40%. Epigallocatechin-3-gallate failed to alter S-phase cell cycle arrest induced by cisplatin and to modulate cisplatin effects on mitochondrial function. These results indicate that pre-treatment with EGCG could be used as an adjunctive therapy to maximise effectiveness of chemotherapy.Entities:
Keywords: Cisplatin; apoptosis; cell cycle arrest; cytotoxicity; epigallocatechin-3-gallate; mitochondria
Mesh:
Substances:
Year: 2017 PMID: 28641455 DOI: 10.1080/14786419.2017.1343318
Source DB: PubMed Journal: Nat Prod Res ISSN: 1478-6419 Impact factor: 2.861